For the estimated 60,000 Americans living with acromegaly — a condition of chronic growth hormone excess that accelerates cardiovascular disease, joint destruction, and premature mortality — the choice of long-term medical therapy matters enormously. A Bayesian network meta-analysis now offers the most rigorous indirect comparison of available treatments to date, with implications for both quality of life and disease control.
Drawing on 18 randomized controlled trials identified through MEDLINE and Embase and following PRISMA methodology, researchers quantified biochemical control rates and treatment discontinuations across seven pharmacological classes. Most injectable somatostatin receptor ligands (SRLs) — including lanreotide autogel, octreotide LAR, and pasireotide — achieved broadly comparable biochemical control. However, two distinctions emerged. Pasireotide demonstrated significantly superior biochemical control versus octreotide LAR (odds ratio 2.03, 95% credible interval 1.29–3.23). More strikingly, the once-daily oral SRL paltusotine showed biochemical control roughly 7-fold higher than both oral octreotide and subcutaneous octreotide depot formulations, with discontinuation rates due to adverse events more than 40-fold lower versus those same comparators.
These findings land at a pivotal moment for acromegaly management. Injectable SRLs remain the backbone of medical therapy, but adherence challenges with monthly depot injections are well-documented in real-world practice. Oral alternatives have long been pursued, yet earlier formulations struggled with gastrointestinal tolerability and erratic absorption. Paltusotine's profile here is notable because it suggests the oral route need not mean compromised efficacy or worsened tolerability — a combination that could reshape prescribing if confirmed in longer-term post-approval data. Critical limitations include the relatively small number of RCTs in acromegaly overall, heterogeneity in patient populations, and the indirect nature of network comparisons. Head-to-head trials between paltusotine and injectable SRLs would substantially strengthen confidence. Still, this analysis represents a meaningful step toward evidence-based treatment sequencing in a disease where rigorous comparative data have historically been scarce.